YHD 1023

Drug Profile

YHD 1023

Alternative Names: YHD1023

Latest Information Update: 18 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Erectile dysfunction therapies
  • Mechanism of Action Nitric oxide synthase stimulants; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Erectile dysfunction

Most Recent Events

  • 18 Sep 2014 No development reported - Phase-II for Erectile dysfunction in South Korea (PO)
  • 01 Mar 2013 Yuhan Corporation completes a phase II trial in Erectile dysfunction in South Korea (NCT01423370)
  • 30 Nov 2011 Phase-II clinical trials in Erectile dysfunction in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top